In a report released today, Josh Jennings from TD Cowen maintained a Buy rating on Vericel, with a price target of $55.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Josh Jennings has given his Buy rating due to a combination of factors that suggest Vericel is poised for a strong performance. The company is expected to deliver robust results in the second quarter, driven by continued contributions from its MACI product and improvements in its Burn Care unit. This anticipated performance is likely to set the stage for accelerated revenue growth in the latter half of 2025, supported by new product offerings and ongoing profitability.
Jennings’s confidence in Vericel’s growth is bolstered by the expansion of the MACI Arthro solution, which has been gaining traction among surgeons. The company has trained a significant number of surgeons, and those trained have shown higher growth rates in biopsy and implant procedures compared to their untrained counterparts. This momentum, along with the existing MACI offerings, is expected to push revenues towards the upper end of the company’s guidance, reinforcing the Buy rating.
In another report released on July 14, BTIG also maintained a Buy rating on the stock with a $51.00 price target.